The CRISPR patent battle will now be elevated to the US Court of Appeals as two major research institutions fight for control over the gene editing technique.
A team of researchers harnessed the CRISPR-Cas9 gene editing technology to correct mutations in the protein that causes a very rare immunodeficiency disorder.
A team of scientists said they developed a new and improved version of the CRISPR/Cas9 gene editing system, EXACT, which acts like a band-aid for genes.
A team of scientists found a way to turn off modifications done by the CRISPR-Cas9 gene editing system.
The doctors harvested immune cells from the blood of the patient and using CRISPR disabled that protein PD-1, which have been known to help cancer cells grow. These cells were multiplied and injected back to the patient, hoping that the edited cells will stop the lung cancer from further advancing. The Chinese trial is the first time that CRISPR was used as a cancer cure and in treating live human patients.